| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8650886 | American Heart Journal | 2018 | 32 Pages |
Abstract
A bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gerald MD, Mathieu MD, Arzu MD, Yuyin MS, Roxana MD, Christoph MD, Jonathan L. MD, Freek W.A. MD, Peter PhD, Martin MD, Gregory Y.H. MD, Marc MD, Eric D. MD, MPH, Keith A.A. MBChB, C. Michael MS, MD,